Last reviewed · How we verify
KPL-404
At a glance
| Generic name | KPL-404 |
|---|---|
| Also known as | abiprubart |
| Sponsor | Kiniksa Pharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease (PHASE2)
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPL-404 CI brief — competitive landscape report
- KPL-404 updates RSS · CI watch RSS
- Kiniksa Pharmaceuticals, Ltd. portfolio CI